CoChat

Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments

Open access
Tinsley, Grant M, Heymsfield, Steven B · 2024 · Journal of the Endocrine Society

The DOI matches its Crossref record; 63 of the 66 references it cites were found in a registry or an index; 35 of the 66 sources its claims cite were checked for support.

Abstract

During weight loss, reductions in body mass are commonly described using molecular body components (eg, fat mass and fat-free mass [FFM]) or tissues and organs (eg, adipose tissue and skeletal muscle). While often conflated, distinctions between body components established by different levels of the 5-level model of body composition-which partitions body mass according to the atomic, molecular, cellular, tissue/organ, or whole-body level-are essential to recall when interpreting the composition of weight loss. A contemporary area of clinical and research interest that demonstrates the importance of these concepts is the discussion surrounding body composition changes with glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in regard to changes in FFM and skeletal muscle mass. The present article emphasizes the importance of fundamental principles when interpreting body composition changes experienced during weight loss, with a particular focus on GLP-1RA drug trials. The potential for obligatory loss of FFM due to reductions in adipose tissue mass and distribution of FFM loss from distinct body tissues are also discussed. Finally, selected countermeasures to combat loss of FFM and skeletal muscle, namely resistance exercise training and increased protein intake, are presented. Collectively, these considerations may allow for enhanced clarity when conceptualizing, discussing, and seeking to influence body composition changes experienced during weight loss.

Overview

CoChat Summary

## TL;DR

This article is a conceptual review arguing that body composition changes during GLP-1RA-associated weight loss need to be interpreted using fundamental body composition principles, especially the distinction between fat-free mass (FFM) and skeletal muscle mass. It also highlights resistance training and higher protein intake as plausible countermeasures to help preserve FFM and muscle during weight loss.

## Key findings

  • The paper emphasizes that FFM and skeletal muscle are not interchangeable: FFM is a molecular-level construct, while skeletal muscle is an organ/tissue-level component, and the two can change differently during weight loss.
  • Historical and contemporary weight-loss literature support a rough “quarter FFM” heuristic, but the proportion of weight lost as FFM varies by method and context; the paper reports median FFM losses of 14% for low-calorie diets and ~23% for very low-calorie diets, and 18% to 31% across specific surgical operations.
  • The paper gives an example where, after a 9.5-kg loss of body mass, 1.5 kg was FFM loss; of that FFM loss, 0.9 kg (60%) was estimated to come from skeletal muscle, 0.1 kg (7%) from kidney/heart/liver, and 0.5 kg (33%) from adipose tissue fat-free component, GI tract, skin, or other sources.
  • In a GLP-1RA-related example, adding exercise to liraglutide led to −4.7 kg FM with +0.5 kg FFM, whereas liraglutide alone led to −2.0 kg FM with 0.0 kg FFM; exercise alone produced +2.1 kg FFM with no statistically significant FM loss.
  • The paper cites protein-intake studies suggesting benefits at higher intakes, including 1.6 g/kg during a 40% energy deficit, 1.1 to 1.6 g/kg outperforming 0.6 to 0.9 g/kg, and improved FFM retention with diets providing ≥25% of energy or >1.0 g/kg; it suggests 1.2 g/kg or greater or 20% or greater of total energy as a practical target.

## Methods

  • This is a narrative/conceptual review focused on body composition principles relevant to interpreting GLP-1RA weight-loss trials, not an original empirical study.
  • The authors state that they searched the historical and contemporary body composition literature for research establishing fundamental principles or illustrating body composition changes.
  • The analysis is interpretive and comparative, using prior studies, theoretical corrections for obligatory FFM loss from adipose tissue, and examples from GLP-1RA, exercise, and protein-intake literature.

## Limitations

  • The paper explicitly notes that direct comparisons within contemporary GLP-1RA trials are needed to establish whether FFM losses are similar across treatment types.
  • It states there is currently a lack of research examining the effects of resistance training alongside GLP-1RA administration, so conclusions about that combination remain provisional.
  • It also says there is limited research to inform differential protein requirements with GLP-1RA treatment, and that more work is warranted on nutrient intake and protein manipulation.
  • Evident from the text: much of the discussion is conceptual and illustrative, relying on prior studies and theoretical adjustments rather than new data collected in this paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/jendso/bvae164

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. The 5-level model of body composition. Adapted with permission from Wang et al [6]. Proportions are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10]. Abbreviations: ECF, extracellular fluid; ECS, extracellular solids.
Figure 1. The 5-level model of body composition. Adapted with permission from Wang et al [6]. Proportions are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10]. Abbreviations: ECF, extracellular fluid; ECS, extracellular solids.CC BY · PubMed Central
Figure 2. Interrelationships between molecular and organ/tissue levels of body composition assessment. Solid arrows indicate the molecules within anatomically defined organ/tissue components (ie, skeletal muscle and adipose tissue) contributing to molecular-level components (ie, fat-free mass and fat mass). “Fat” refers to nonpolar lipids, mainly triglycerides. In contrast, structural or polar lipids (eg, phospholipids, sphingomyelin), historically termed “essential fat,” are included within fat-free components. The dashed line indicates the small contribution of skeletal muscle triglyceride to fat mass. The small unlabeled portion at the top of the skeletal muscle mass stacked bar corresponds to the residual content of skeletal muscle (ie, fat, mineral, structural lipids, glycogen, and other small components). The bracketed portion of the adipose tissue mass stacked bar corresponds to the fat-free (lean) component of adipose tissue, containing water, protein, mineral, structural lipids, glycogen, and other small components. Data are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10].
Figure 2. Interrelationships between molecular and organ/tissue levels of body composition assessment. Solid arrows indicate the molecules within anatomically defined organ/tissue components (ie, skeletal muscle and adipose tissue) contributing to molecular-level components (ie, fat-free mass and fat mass). “Fat” refers to nonpolar lipids, mainly triglycerides. In contrast, structural or polar lipids (eg, phospholipids, sphingomyelin), historically termed “essential fat,” are included within fat-free components. The dashed line indicates the small contribution of skeletal muscle triglyceride to fat mass. The small unlabeled portion at the top of the skeletal muscle mass stacked bar corresponds to the residual content of skeletal muscle (ie, fat, mineral, structural lipids, glycogen, and other small components). The bracketed portion of the adipose tissue mass stacked bar corresponds to the fat-free (lean) component of adipose tissue, containing water, protein, mineral, structural lipids, glycogen, and other small components. Data are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10].CC BY · PubMed Central
Figure 3. Potential contributors to the proportion of weight lost as fat-free mass. Adapted with permission from Heymsfield et al [20]. ΔFFM/ΔW, change in fat-free mass relative to the change in weight.
Figure 3. Potential contributors to the proportion of weight lost as fat-free mass. Adapted with permission from Heymsfield et al [20]. ΔFFM/ΔW, change in fat-free mass relative to the change in weight.CC BY · PubMed Central
Figure 4. Adjustment of fat-free mass changes for obligatory loss of the fat-free component of adipose tissue. The fat-free component of adipose tissue (FFAT) is approximated from fat mass changes reported by contemporary glucagon-like peptide-1 receptor agonist (GLP-1RA) trials as: FFAT≈Fatmass/0.85×0.15, when assuming that all fat mass loss is derived from adipose tissue and the fat content of adipose tissue is 85% [26, 27]. The fat-free component of adipose tissue is then subtracted from the reported fat-free mass changes, due to its obligatory nature, to provide an adjusted estimate of fat-free mass loss from non-adipose tissues. Data were obtained from published GLP-1RA trials [31-36].
Figure 4. Adjustment of fat-free mass changes for obligatory loss of the fat-free component of adipose tissue. The fat-free component of adipose tissue (FFAT) is approximated from fat mass changes reported by contemporary glucagon-like peptide-1 receptor agonist (GLP-1RA) trials as: FFAT≈Fatmass/0.85×0.15, when assuming that all fat mass loss is derived from adipose tissue and the fat content of adipose tissue is 85% [26, 27]. The fat-free component of adipose tissue is then subtracted from the reported fat-free mass changes, due to its obligatory nature, to provide an adjusted estimate of fat-free mass loss from non-adipose tissues. Data were obtained from published GLP-1RA trials [31-36].CC BY · PubMed Central
Figure 5. Hypothetical distribution of fat-free mass and skeletal muscle loss during weight loss. Relationships between total fat-free mass loss and loss of fat-free mass from specific tissues and organs presented by Bosy-Westphal et al [29] are hypothetically applied to fat-free mass loss with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reported by Wilding et al [34]. While the proportions between fat-free mass loss may vary between weight loss methods, the data are illustrative of the multiple tissue or organ sources contributing to fat-free mass loss.
Figure 5. Hypothetical distribution of fat-free mass and skeletal muscle loss during weight loss. Relationships between total fat-free mass loss and loss of fat-free mass from specific tissues and organs presented by Bosy-Westphal et al [29] are hypothetically applied to fat-free mass loss with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reported by Wilding et al [34]. While the proportions between fat-free mass loss may vary between weight loss methods, the data are illustrative of the multiple tissue or organ sources contributing to fat-free mass loss.CC BY · PubMed Central

Verification

Claims the paper makes

31 Valid · 0 Not valid · 20 Not checked · 7 Own results and interpretations

33 more claims · 16 with their cited sources checked

Create a free account to see all 58 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Cited by

See all 81

Metadata

Authors
Tinsley, G. M., & Heymsfield, S. B.
Affiliations
  • Texas Tech University (US)
  • Pennington Biomedical Research Center (US)
Corresponding author
Tinsley, Grant M
Venue
Journal of the Endocrine Society
Published
2024-09-25
Volume
8
Issue
11
Pages
bvae164-bvae164
ISSN
2472-1972 (ISSN-L)
OpenAlex
W4402834318
Cited by
81
References
66
Citations by year
2026: 42 · 2025: 37 · 2024: 2
FWCI
4.60
Type
journal article
Language
en
Open access
Locations
  • Journal of the Endocrine Society (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
Keywords
body composition, fat-free mass, skeletal muscle mass, GLP-1 receptor agonists, weight loss, adipose tissue, resistance training, protein intake

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.